Mullen L, Chamberlain G, Sacre S. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res Ther. 2015;17(1).
Bryant C, Gay N, Heymans S, Sacre S, Schaefer L, Midwood K. Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. Critical Reviews in Biochemistry and Molecular Biology. 2015;50(5):359-379.
Salzano S, Checconi P, Hanschmann E, Lillig C, Bowler L, Chan P et al. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proceedings of the National Academy of Sciences. 2014;111(33):12157-12162.
Thwaites R, Chamberlain G, Sacre S. Emerging Role of Endosomal Toll-Like Receptors in Rheumatoid Arthritis. Front Immunol. 2014;5.
Alzabin S, Kong P, Medghalchi M, Palfreeman A, Williams R, Sacre S. Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Res Ther. 2012;14(3):R142.
Clanchy F, Sacre S. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease. Expert Opinion on Biological Therapy. 2010;10(12):1703-1716.
Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis & Rheumatism. 2010;62(3):683-693.
Midwood K, Piccinini A, Sacre S. Targeting Toll-like Receptors in Autoimmunity. Current Drug Targets. 2009;10(11):1139-1155.
Midwood K, Sacre S, Piccinini A, Inglis J, Trebaul A, Chan E et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nature Medicine. 2009;15(7):774-780.